Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm 3 : A Post Hoc Analysis from the ANANKE Study.

MLA

Senna, Gianenrico, et al. “Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/Mm 3 : A Post Hoc Analysis from the ANANKE Study.” Journal of Asthma and Allergy, vol. 15, Nov. 2022, pp. 1593–604. EBSCOhost, https://doi.org/10.2147/JAA.S383012.

APA

Senna, G., Aliani, M., Altieri, E., Bracciale, P., Brussino, L., Caiaffa, M. F., Cameli, P., Canonica, G. W., Caruso, C., D’Amato, M., De Michele, F., Del Giacco, S., Di Marco, F., Menzella, F., Pelaia, G., Rogliani, P., Romagnoli, M., Schino, P., Schroeder, J. W., … Centanni, S. (2022). Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm 3 : A Post Hoc Analysis from the ANANKE Study. Journal of Asthma and Allergy, 15, 1593–1604. https://doi.org/10.2147/JAA.S383012

Chicago

Senna, Gianenrico, Maria Aliani, Elena Altieri, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Paolo Cameli, et al. 2022. “Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/Mm 3 : A Post Hoc Analysis from the ANANKE Study.” Journal of Asthma and Allergy 15 (November): 1593–1604. doi:10.2147/JAA.S383012.